TY - JOUR T1 - Genome-wide meta-analysis of over 29,000 people with epilepsy reveals 26 loci and subtype-specific genetic architecture JF - medRxiv DO - 10.1101/2022.06.08.22276120 SP - 2022.06.08.22276120 AU - International League Against Epilepsy Consortium on Complex Epilepsies AU - Samuel F Berkovic AU - Gianpiero L Cavalleri AU - Bobby PC Koeleman Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/06/14/2022.06.08.22276120.abstract N2 - Epilepsy is a highly heritable disorder affecting over 50 million people worldwide, of which about one-third are resistant to current treatments. Here, we report a trans-ethnic GWAS including 29,944 cases, stratified into three broad- and seven sub-types of epilepsy, and 52,538 controls. We identify 26 genome-wide significant loci, 19 of which are specific to genetic generalized epilepsy (GGE). We implicate 29 likely causal genes underlying these 26 loci. SNP-based heritability analyses show that common variants substantially close the missing heritability gap for GGE. Subtype analysis revealed markedly different genetic architectures between focal and generalized epilepsies. Gene-set analysis of GGE signals implicate synaptic processes in both excitatory and inhibitory neurons in the brain. Prioritized candidate genes overlap with monogenic epilepsy genes and with targets of current anti-seizure medications. Finally, we leverage our results to identify alternate drugs with predicted efficacy if repurposed for epilepsy treatment.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study received support from Science Foundation Ireland (SFI) (16/RC/3948), co-funded under the European Regional Development Fund, the Research Unit FOR-2715 of the German Research Foundation (MN: NO755/6-1, NO755/13-1), from Wellcome Trust (grant 084730), European Unions Seventh Framework Programme (FP7/2007-2013) under grant agreement n279062 (EpiPGX), The Muir Maxwell Trust and the Epilepsy Society, UK. Part of this work was undertaken at University College London Hospitals, which received a proportion of funding from the NIHR Biomedical Research Centres funding scheme. RS and BPCK are supported by an Vrienden WKZ fund 1616091 (MING). SFB and IES are supported by a National Health and Medical Research Council (NHMRC) of Australia Program Grant [1091593]. MB is supported by an NHMRC Investigator grant [APP1195236]. KLO is supported by an Australian Government Research Training Program Scholarship [APP533086] provided by the Australian Commonwealth Government and the University of Melbourne. DLS identified data from people predicted to have epilepsy form the UK Biobank while funded by a Wellcome Clinical PhD Fellowship on the 4ward North program [203914/Z/16/Z]. MRJ was supported by the UKRI MRC Award No: MR/S02638X/1 and by the NIHR Imperial Biomedical Research Centre (BRC). Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), Brazil, grant number (2013/07559-3). The funding bodies had no role in the study design, data collection, analysis, and interpretation, or in writing the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Local institutional review boards approved study protocols at each contributing site. All study participants provided written, informed consent for use of their data in genetic studies of epilepsy. For minors, written informed consent was obtained from their parents or legal guardian. The following ethics committees/IRBs gave approval for this work: Research Ethics Committee at the University of Campinas (UNICAMP), Brazil; Thomas Jefferson University Hospital Philadelphia PA USA; The University of Pensylvania, Philadelphia PA USA; The University of Cincinnati, Cincinnati Ohio USA; Beth Israel Deaconess Medical Center, Boston MA; The University of Montreal, Montreal Quebec, CA; Duke University Institutional Review Board, Durham, NC, USA; Montefiore Medical Center Institutional Review Board; Hospital General de Agudos J.M.Ramos Mejia Comite de Etica en Investigacion; Children's Hospital Boston Office of Clinical Investigation; University of Pittsburgh Institutional Review Board; Children's Hospital of Philadelphia Committees for Protection of Human Subjects; Cincinnati Children's Hospital Medical Center Institutional Review Board; Cleveland Clinic Institutional Review Board; Columbia University Medical Center; Colorado Multiple Institutional IRB Board; Emory University Institutional Review Board; Ethics Committee at the Medical Faculty of the Eberhard Karls University and the University Hospital Tubingen; University Hospital of Bonn Ethical Committee; Medical Ethical Board of the University Medical Center Utrecht, The Netherlands; Ethics Committee at the Medical Faculty of the EberhardKarls University and the University Hospital Tubingen; University Hospital of Bonn Ethical Committee; Medical Ethical Board of the University Medical Center Utrecht, The Netherlands; Joint Research Ethics Committee, National Hospital for Neurology and Neurosurgery and Institute of Neurology, 00/N081 NRES Committee London, Camden & Islington; North West 3 Research Ethics Committee in April 2010 (ref: 10/H1002/5); NorthWest Multicentre Research Ethics Committee (ref: MREC 02/8/45); West Ethics Committee, North Glasgow University Hospitals NHS Trust (ref: 02/119(2); METC 09-352K: The Genetics of epilepsy; Beaumont Hospital Ethics Committee (study code 02/44; University Hospital of Bonn Ethical Committee; Suomen valtakunnallinen laaketieteellinen tutkimuseettinen toimikunta TUKIJA; University Hospital of Bonn Ethical Committee (040/07); Coordinating Ethics Committee of The Hospital District of Helsinki and Uusimaa; Ethics Committee of the Bavarian Medical Association (Bayerische Landesarztekammer); North West Multicentre Research Ethics Committee, Manchester, UK; The Erasmus ULB Ethics Committee, Brussels; NRES Committee, Yorkshire and the Humber Leeds West, UK (Reference 05/Q1205/35); The ethics commission of the Faculty of Medicine of the Christian Albrechts University of Kiel (CAU); Beaumont Hospital Ethics Committee; St James Hospital and Adelaide and Meath Hospital Research Ethics Committee; Melbourne Health Human Research and Ethics Committee; Dublin Federated Hospitals Research Ethics Committee; NRES Committee London Camden & Islington; The Erasmus ULB Ethics Committee, Brussels; University Hospital of Bonn Ethical Committee (040/07); The Joint Chinese University of Hong Kong New Territories East Cluster Clinical Research Ethics Committee; North West Haydock Research Ethics Committee; NRES Committee London Camden & IslingtonI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe GWAS summary statistics data that support the findings of this study (for both trans-ethnic and European-only analyses) are available at https://www.epigad.org/. https://www.epigad.org/ ER -